Stella Pharma Corporation
Contract signing for development and sales partnership with CBSH and Pengbo for expansion into the Mainland China market
To expand BNCT in Mainland China, a development and sales partnership agreement was signed with CBSH and Pengbo. Aims to obtain Chinese approvals and establish a sales framework, anticipating mid-term business expansion.
Key Figures
- Key figure 1: Unknown (no specific amounts or shares are disclosed)
- Key figure 2: Unknown (approval timing and start of sales are not disclosed)
- Key figure 3: Unknown (no quantitative information on sales contribution)
AI要約
Overview of the partnership
This partnership aims to establish a development and sales framework to supply Stellar Pharma's BNCT drug 'Stavronin' to Mainland China, in collaboration with CBSH and Pengbo to pursue NMPA approval. As the overseas MAH, the company will provide data and support, designate a local agent, and set up a total import agent in preparation for post-approval sales arrangements.
Outlook and medium-to-long-term impact
The collaboration is a mid- to long-term strategic partnership aimed at obtaining approval and expanding sales, with a minor anticipated impact on fiscal year ending March 2027. It could lead to BNCT adoption and business expansion in the Chinese market, though specific numerical impacts are not yet determined.
Stellarama Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
